---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-048597"
form_type: "8-K"
ticker: "ESLA"
cik: "0001844417"
company_name: "Estrella Immunopharma, Inc."
filed_at: "2025-05-29T23:59:59+00:00"
generated_at: "2026-05-20T06:26:38.789046+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Estrella Immunopharma doses first patient in STARLIGHT-1 second cohort for EB103 in NHL

## Summary
- First patient dosed in second cohort of Phase I/II STARLIGHT-1 trial evaluating EB103 at higher dose.
- No dose-limiting toxicities or treatment-related serious adverse events observed in first cohort.
- Complete response reported in first cohort; trial targets advanced B-cell non-Hodgkin's lymphomas.
- CEO Cheng Liu highlights potential for HIV-associated and CNS lymphoma patients currently excluded from CAR-T.

## SEC filing metadata
- accession: 0001213900-25-048597
- form_type: 8-K
- ticker: ESLA
- cik: 0001844417
- company_name: Estrella Immunopharma, Inc.
- filed_at: 2025-05-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1844417/000121390025048597/0001213900-25-048597-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1844417/000121390025048597/ea0243703-8k_estrella.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-048597
- JSON: https://secwatch.observer/filing/0001213900-25-048597.json
- Plain text: https://secwatch.observer/filing/0001213900-25-048597.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.